Tuesday, April 16, 2013,
Ashok Niroula
| If you can't see this message please use this link |
Human Clinical Trials Using Medical Marijuana Could Be Close in the U.S.
With more and more acceptance of medical marijuana here in the U.S., companies like Nuvilex, Inc. (OTCQB: NVLX), and research centers like the California Pacific Medical Center in San Francisco are pleased to see momentum building and opinions changing. As Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., lays the groundwork to begin studying different forms of cancer, it may very well be work like that done by doctors at California Pacific Medical Center that helps lay the groundwork for the industry to conduct human clinical trials.
The use of marijuana for medicinal purposes by those patients suffering from cancer is nothing new. However, the dramatic shift in opinion toward the drug in this country is new. As we've reported before, a recent Pew Research Center poll showed for the first time in 44 years of polling on the topic, that a majority of Americans were in favor of legalizing marijuana. This new shift could very well put pressure on those in Washington, D.C. and the remaining states that have not passed legislation legalizing marijuana or at the very least the compounds found in the drug that may prove vital to cancer research.
First in line at a shot at human clinical trials, could very well be a number of researchers at California Pacific Medical Center. Much like Nuvilex's subsidiary, they will initially utilize cannabidiol (CBD) as the basis for developing treatments for some of the deadliest forms of cancer. The group of doctors at California Pacific Medical Center has been working for more than five years studying cannabidiol which is one of the compounds found in Cannabis. CBD is non-toxic and unlike THC, it is not psychoactive which could very well gain it favor among the drug's detractors.
Two of the researchers involved in the study using CBD, Sean McAllister, Ph.D., and Pierre Desprez, Ph.D., both believe their work is ready for human trials, using the compound to treat metastatic cancer.
end of news release....
We start off our week with a TITAN ALERT........Nuvilex, Inc. (NVLX)
The medical cannabis industry was valued at 1.3 billion in 2011, but with legalization spreading through states at a blistering pace…What they see in growth potential is staggering.
THIS INDUSTRY IS PROJECTED FOR
600%+ GROWTH IN 5 YEARS!
600%+ GROWTH IN 5 YEARS!
Simply one of the hottest industries on Wall Street today is the medical marijuana industry with experts predicting exponential growth in the mid-term. It's been the topic of television specials on CNBC and CBS's 60 Minutes as well as articles in leading financial publications like MarketWatch, Reuters, Bloomberg and more. When analysts are touting the potential, we need to be listening
Nuvilex, Inc. (NVLX), with their new subsidiary Medical Marijuana Sciences, Inc., could be the next company that experts are focused on in the coming days to deliver transformational profits to their portfolio!
Nuvilex (NVLX) is firmly entrenched in the emerging industry with a one-of-a-kind technology as THE ONLY pure biotechnology play in the business.
Nuvilex has unlimited upside potential because its proprietary living cell encapsulation technology is a true platform that has could serve a benefit to countless indications. The experts at Nuvilex also intend to utilize cannabinoids (active ingredients in marijuana) in developing treatments for an array of diseases and conditions, through its subsidiary Medical Marijuana Sciences, Inc. So, the company appears to be in an ideal situation to develop combination treatments that use both technologies for deadly diseases, such as pancreatic cancer.
There are more than 70 cannabinoids found in marijuana that have proven therapeutic benefits with analgesic, sedative, anti-inflammatory, anticonvulsant, and antispasmodic effects that have been used for more than 3,000 years. Additionally, cannabinoids have been known to alleviate pain, nausea, and vomiting. These compounds have been particularly effective against cancer-related pain and in enhancing the appetites of cancer patients that are typically diminished. The latter discovery has led to finding that cannabinoids can help relieve cancer-related cachexia, a "wasting" syndrome composed of weight loss, muscle atrophy, fatigue, weakness, and loss of appetite.
The core competency of Nuvilex is its cell encapsulation technology that has been shown in the lab and clinic to possibly be one of the most effective delivery systems in for targeted and sustained therapy of pancreatic cancer. The technology can be used to encapsulate any type of living cells to deliver focused treatment to the afflicted site. A stark reduction in side effects typically associated with chemotherapy is possible too because by using cell encapsulation-based treatment, lower doses of cancer drugs may be used. Of course, the offerings of Medical Marijuana Sciences will be there to treat those that do manifest as well. It's a win-win for patients and oncology!
Brain, Spine and Pancreatic Cancers will claim the lives of 52,000 people in the U.S. in 2013. Research shows that Nuvilex could potentially help this area of great unmet medical need!
To get only a sampling of what is possible with Nuvilex's cell encapsulation franchise, consider just pancreatic cancer and glioblastoma multiforme (brain cancer). Both are basically considered death sentences to patients who get diagnosed with survival times generally measured in months (and often times weeks), not years.
45,000 new cases of pancreatic cancer will be diagnosed in the U.S. in 2013 with 38,000 people dying from the disease this year. Gemzar, a drug by Eli Lilly (LLY) is the only FDA-approved treatment (and, unfortunately, not very effective), generated about 1.4 BIL in sales in 2010. CNBC's Jim Cramer recently postulated that a new pancreatic cancer drug would be worth at least 2 BIL annually.
Jordan S Terry wrote wrote on Forbes.com about Nuvilex,
"this company, on a stand-alone basis, could change the way cancer, diabetes, and other horrible diseases are treated if not cured. Additionally, it's a play on the inevitable paradigm shift in medical technologies coming from cell therapy and stem cell advancements."
This one could be a real TITAN in the marijuana market.
As detailed in a recent article in the Los Angeles Times about the burgeoning marijuana market, "Wall Street has good reasons to smell potential profits."
If you see the TITAN potential in NVLX like we do, then we will see yoou at the bell !
titanstockalerts has been compensated up to five thousand dollars by a third party for this email advertisement.
Nuvilex, Inc. (NVLX), with their new subsidiary Medical Marijuana Sciences, Inc., could be the next company that experts are focused on in the coming days to deliver transformational profits to their portfolio!
Nuvilex (NVLX) is firmly entrenched in the emerging industry with a one-of-a-kind technology as THE ONLY pure biotechnology play in the business.
Nuvilex has unlimited upside potential because its proprietary living cell encapsulation technology is a true platform that has could serve a benefit to countless indications. The experts at Nuvilex also intend to utilize cannabinoids (active ingredients in marijuana) in developing treatments for an array of diseases and conditions, through its subsidiary Medical Marijuana Sciences, Inc. So, the company appears to be in an ideal situation to develop combination treatments that use both technologies for deadly diseases, such as pancreatic cancer.
There are more than 70 cannabinoids found in marijuana that have proven therapeutic benefits with analgesic, sedative, anti-inflammatory, anticonvulsant, and antispasmodic effects that have been used for more than 3,000 years. Additionally, cannabinoids have been known to alleviate pain, nausea, and vomiting. These compounds have been particularly effective against cancer-related pain and in enhancing the appetites of cancer patients that are typically diminished. The latter discovery has led to finding that cannabinoids can help relieve cancer-related cachexia, a "wasting" syndrome composed of weight loss, muscle atrophy, fatigue, weakness, and loss of appetite.
The core competency of Nuvilex is its cell encapsulation technology that has been shown in the lab and clinic to possibly be one of the most effective delivery systems in for targeted and sustained therapy of pancreatic cancer. The technology can be used to encapsulate any type of living cells to deliver focused treatment to the afflicted site. A stark reduction in side effects typically associated with chemotherapy is possible too because by using cell encapsulation-based treatment, lower doses of cancer drugs may be used. Of course, the offerings of Medical Marijuana Sciences will be there to treat those that do manifest as well. It's a win-win for patients and oncology!
Brain, Spine and Pancreatic Cancers will claim the lives of 52,000 people in the U.S. in 2013. Research shows that Nuvilex could potentially help this area of great unmet medical need!
To get only a sampling of what is possible with Nuvilex's cell encapsulation franchise, consider just pancreatic cancer and glioblastoma multiforme (brain cancer). Both are basically considered death sentences to patients who get diagnosed with survival times generally measured in months (and often times weeks), not years.
45,000 new cases of pancreatic cancer will be diagnosed in the U.S. in 2013 with 38,000 people dying from the disease this year. Gemzar, a drug by Eli Lilly (LLY) is the only FDA-approved treatment (and, unfortunately, not very effective), generated about 1.4 BIL in sales in 2010. CNBC's Jim Cramer recently postulated that a new pancreatic cancer drug would be worth at least 2 BIL annually.
Jordan S Terry wrote wrote on Forbes.com about Nuvilex,
"this company, on a stand-alone basis, could change the way cancer, diabetes, and other horrible diseases are treated if not cured. Additionally, it's a play on the inevitable paradigm shift in medical technologies coming from cell therapy and stem cell advancements."
This one could be a real TITAN in the marijuana market.
As detailed in a recent article in the Los Angeles Times about the burgeoning marijuana market, "Wall Street has good reasons to smell potential profits."
If you see the TITAN potential in NVLX like we do, then we will see yoou at the bell !
titanstockalerts has been compensated up to five thousand dollars by a third party for this email advertisement.
| Unsubscribe from Future Mailings. Update your Preferences. Didn't sign up for this? Report it. |
Posts
